Effect of Bundled Interventions to Reduce Surgical Site Infection after Gynecologic Cancer Surgery: A Randomized Clinical Trial

Abstract

Background: Patients can avoid surgical site infections (SSIs), which are a known cause of morbidity and death. They follow between 10  and 35 percent of gynecologic oncology operations performed globally.

Objective: To assess how bundled therapies affect the reduction  of SSI following gynecologic cancer surgery.

Patients and methods: Between January and December 2019, a tertiary university hospital  conducted a single-center open-labeled randomised clinical study. Fifty women with gynecological cancer procedures were recruited in  the trial and were randomly assigned in a 1:1 ratio to either bundled care (group I) or normal hospital care (group II). Overall surgery site  infection was the main result, while duration of hospital stays and readmissions were the secondary results, etc.

Results: The overall  infection rate was 20% in group I and 64% in group II (p= 0.002). The length of hospital stays; was 4.68 ± 3.437 days in group I and 8.48  ±7.171 days in group II (P= .021).

Conclusion: Significant decreases in SSIs and length of hospital stays following major gynecologic  cancer surgery were linked to the SSI reduction bundle.

Recommendations: Implementation of the bundled interventions in gynecologic  oncology patients as a routine care and further studies are needed to generalize the results of the current study.